CORDIS
EU research results

CORDIS

English EN
An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics: Targeting function and cross-talk of bacterial Envelope proTein machineries

An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics: Targeting function and cross-talk of bacterial Envelope proTein machineries

Objective

Train2Target is a multidisciplinary European Training Network built to address the challenge of the discovery of alternative antimicrobials. Innovative strategies to deliver a next generation of drugs are urgently needed. The alarming threats and spread of multi-drug resistant bacteria is currently leaving clinicians with very limited options to combat infections especially those from Gram-negative pathogens.

The Train 2Target research programme focuses on the assembly of the well-known bacterial cell envelope from a new perspective. Indeed it aims to inhibit novel targets in envelope biogenesis by altering the function and misbalancing the coordination of envelope assembly machines, which build and assemble the Gram-negative bacterial envelope. A wide variety of chemical classes and compounds sources will be screened using innovative biochemical, biophysical and genetic assays to identify valuable hit scaffolds to be optimized into druggable leads.

The high quality and credibility of our consortium is ensured by a strong interdisciplinary academia-industry partnership to encompass different complementary expertise ranging from microbiology, bacterial genetics, biochemistry, cell imaging, structural biology, biophysics and chemical synthesis. Our 9 academic groups are all renowned leaders in the cell envelope biogenesis field, whereas the complementary 5 SMEs and 3 Industry partners are specialised in drug discovery and development of novel anti-infective drugs. This unique combination of scientific excellence and industrial know-how in drug discovery covers the entire process from the design to the implementation of innovative antibacterial strategies and lead identification.

Train2Target also represents a unique research platform to train 15 Early Stage Researchers and equip them with the necessary scientific and transferable skills that will make them highly competitive for both top European research institutions and the pharma/biotech job market.

Coordinator

UNIVERSITA DEGLI STUDI DI MILANO

Address

Via Festa Del Perdono 7
20122 Milano

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 516 122,64

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 262 875,60

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 546 575,76

UNIVERSITE CATHOLIQUE DE LOUVAIN

Belgium

EU Contribution

€ 501 120

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 510 748,56

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II

Italy

EU Contribution

€ 258 061,32

AICURIS ANTI-INFECTIVE CURES GMBH

Germany

EU Contribution

€ 249 216,48

UNION THERAPEUTICS AS

Denmark

EU Contribution

€ 290 081,88

BIOVERSYS AG

Switzerland

EU Contribution

€ 265 226,76

NAICONS SRL

Italy

EU Contribution

€ 258 061,32

Partners (6)

Sort alphabetically

Expand all

ACCELOPMENT AG

Antabio SAS

Basilea Pharmaceutica Ltd

DANMARKS TEKNISKE UNIVERSITET

UNIVERSITAT BASEL

ZOETIS INTERNATIONAL SERVICES SAS

Project information

Grant agreement ID: 721484

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 931 378,20

  • EU contribution

    € 3 931 378,20

Coordinated by:

UNIVERSITA DEGLI STUDI DI MILANO

Italy